These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 10367950

  • 1. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons.
    Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A.
    Vaccine; 1999 Apr 23; 17(17):2166-75. PubMed ID: 10367950
    [Abstract] [Full Text] [Related]

  • 2. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
    Corbet S, Vinner L, Hougaard DM, Bryder K, Nielsen HV, Nielsen C, Fomsgaard A.
    AIDS Res Hum Retroviruses; 2000 Dec 10; 16(18):1997-2008. PubMed ID: 11153083
    [Abstract] [Full Text] [Related]

  • 3. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo.
    Muthumani K, Zhang D, Dayes NS, Hwang DS, Calarota SA, Choo AY, Boyer JD, Weiner DB.
    Virology; 2003 Sep 15; 314(1):134-46. PubMed ID: 14517067
    [Abstract] [Full Text] [Related]

  • 4. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
    Sakaue G, Hiroi T, Nakagawa Y, Someya K, Iwatani K, Sawa Y, Takahashi H, Honda M, Kunisawa J, Kiyono H.
    J Immunol; 2003 Jan 01; 170(1):495-502. PubMed ID: 12496436
    [Abstract] [Full Text] [Related]

  • 5. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW, Perry HC, Davies ME, Freed DC, Liu MA.
    Ann N Y Acad Sci; 1995 Nov 27; 772():198-208. PubMed ID: 8546393
    [Abstract] [Full Text] [Related]

  • 6. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
    Barnett SW, Rajasekar S, Legg H, Doe B, Fuller DH, Haynes JR, Walker CM, Steimer KS.
    Vaccine; 1997 Jun 27; 15(8):869-73. PubMed ID: 9234536
    [Abstract] [Full Text] [Related]

  • 7. Anti-HIV env immunities elicited by nucleic acid vaccines.
    Shiver JW, Davies ME, Yasutomi Y, Perry HC, Freed DC, Letvin NL, Liu MA.
    Vaccine; 1997 Jun 27; 15(8):884-7. PubMed ID: 9234539
    [Abstract] [Full Text] [Related]

  • 8. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses.
    Liu LJ, Watabe S, Yang J, Hamajima K, Ishii N, Hagiwara E, Onari K, Xin KQ, Okuda K.
    Vaccine; 2001 Oct 12; 20(1-2):42-8. PubMed ID: 11567744
    [Abstract] [Full Text] [Related]

  • 9. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
    Fomsgaard A, Nielsen HV, Bryder K, Nielsen C, Machuca R, Bruun L, Hansen J, Buus S.
    Scand J Immunol; 1998 Apr 12; 47(4):289-95. PubMed ID: 9600309
    [Abstract] [Full Text] [Related]

  • 10. Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.
    Megati S, Garcia-Hand D, Cappello S, Roopchand V, Masood A, Xu R, Luckay A, Chong SY, Rosati M, Sackitey S, Weiner DB, Felber BK, Pavlakis GN, Israel ZR, Smith LR, Eldridge JH, Sidhu MK, Egan MA.
    Vaccine; 2008 Sep 19; 26(40):5083-94. PubMed ID: 18485543
    [Abstract] [Full Text] [Related]

  • 11. Comparisons of DNA-mediated immunization procedures directed against surface glycoproteins of human immunodeficiency virus type-1 and hepatitis B virus.
    Fomsgaard A, Nielsen HV, Nielsen C, Johansson K, Machuca R, Bruun L, Hansen J, Buus S.
    APMIS; 1998 Jun 19; 106(6):636-46. PubMed ID: 9725796
    [Abstract] [Full Text] [Related]

  • 12. Immunization with HIV-1 subtype B gp160-DNA induces specific as well as cross reactive immune responses in mice.
    Arora A, Seth P.
    Indian J Med Res; 2001 Jul 19; 114():1-9. PubMed ID: 11762199
    [Abstract] [Full Text] [Related]

  • 13. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine.
    Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S, Okuda K, Miyagi Y, Aoki I, Nishioka K, Klinman D, Okuda K.
    J Immunol; 2000 Mar 15; 164(6):3102-11. PubMed ID: 10706700
    [Abstract] [Full Text] [Related]

  • 14. [Immunogenicity of plasmid DNA and adenoviral vectors encoding HIV-1 subtype B env gene].
    Yang HR, Zhang LF, Feng X, Yu SQ, Zhuang ZL, Li HX, Zeng Y.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Dec 15; 24(6):415-7. PubMed ID: 21604562
    [Abstract] [Full Text] [Related]

  • 15. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
    Fuller DH, Haynes JR.
    AIDS Res Hum Retroviruses; 1994 Nov 15; 10(11):1433-41. PubMed ID: 7888198
    [Abstract] [Full Text] [Related]

  • 16. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
    Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ, Kaneko Y, Kozbor D.
    Virology; 2000 Feb 01; 267(1):8-16. PubMed ID: 10648178
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of intranasal immunization with HIV-gp160 and an HIV-1 env CTL epitope peptide (E7) in combination with the mucosal adjuvant LT(R192G).
    Morris CB, Cheng E, Thanawastien A, Cárdenas-Freytag L, Clements JD.
    Vaccine; 2000 Mar 17; 18(18):1944-51. PubMed ID: 10699345
    [Abstract] [Full Text] [Related]

  • 18. Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein.
    Wierzbicki A, Kiszka I, Kaneko H, Kmieciak D, Wasik TJ, Gzyl J, Kaneko Y, Kozbor D.
    Vaccine; 2002 Jan 31; 20(9-10):1295-307. PubMed ID: 11818148
    [Abstract] [Full Text] [Related]

  • 19. Highly potent delivery method of gp160 envelope vaccine combining lentivirus-like particles and DNA electrotransfer.
    Vandermeulen G, Athanasopoulos T, Trundley A, Foster K, Préat V, Yáñez-Muñoz RJ, Dickson G.
    J Control Release; 2012 May 10; 159(3):376-83. PubMed ID: 22310089
    [Abstract] [Full Text] [Related]

  • 20. A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)(HXB2) Rev/Env or codon-optimized HIV-1(JR-FL) gp120 generates durable immune responses in mice.
    Buffa V, Negri DRM, Leone P, Bona R, Borghi M, Bacigalupo I, Carlei D, Sgadari C, Ensoli B, Cara A.
    J Gen Virol; 2006 Jun 10; 87(Pt 6):1625-1634. PubMed ID: 16690927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.